Publications by authors named "Perry Mohammed"

Claim this Profile
C
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.
Cissy Kityo, Ivan K Mambule, Joseph Musaazi, Simiso Sokhela, Henry Mugerwa, Perry Mohammed

Nat Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Cissy Kityo, Ivan K Mambule, Joseph Musaazi, Simiso Sokhela, Henry Mugerwa, Perry Mohammed

Lancet Infect Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study.
Cassidy A Gutner, Marc van der Valk, Joaquin Portilla, Eliette Jeanmaire, Leïla Belkhir, Perry Mohammed

J Int Assoc Provid AIDS Care· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying pediatric patient need for second- and third-line HIV treatment: A tool for decision-making in resource-limited settings.
Perry Mohammed, Andrea Linden, Maura Reilly

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV.
Paula Munderi, Edwin Were, Anchalee Avihingsanon, Pascale A M Mbida, Lerato Mohapi, Perry Mohammed

South Afr J HIV Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial.
Anna Maria Geretti, Mathe Moeketsi, Ralph Demasi, Yvon van Delft, Perry Mohammed

AIDS Res Treat· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?
Pierre-Marie Girard, Mark Nelson, Perry Mohammed, Andrew Hill, Yvon van Delft

AIDS· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in cerebral function parameters in HIV type 1-infected subjects switching to darunavir/ritonavir either as monotherapy or with nucleoside analogues.
Lucy Garvey, Chris Higgs, Perry Mohammed, Andrew Hill, Joanna M Allsop

AIDS Res Hum Retroviruses· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis